Rubius Therapeutics has pulled in another $100 million to fund the advance of its red blood cell therapies. The crossover round, which brings Rubius’ nine-month haul up to $220 million, comes as the ...

On the 10th anniversary of the publication of his first video on the Internet, "Rubius X" is a documentary that deals with the origin, motivation and secrets behind Rubius, one of the most followed ...

Rubius Therapeutics has pulled the plug on its lead drug after its first use in a phase 1b generated “uninterpretable” data. The data capped off a series of setbacks for the phenylketonuria (PKU) ...

Most cell therapies in development use a T cell or some other type of immune cell that’s engineered to perform a particular therapeutic task. Rubius Therapeutics makes its cell therapies from red ...

Rubius Therapeutics went public in 2018 at a $2 billion valuation — the largest biotech stock market debut at that time. On Wednesday, the company — battered down to a market value of $15 million — ...

In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and planned to engage an investment bank to act as a strategic advisor. But ...